Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in -
Benzodiazepine Use and the Risk of Dementia
There is little evidence that older adults prescribed benzodiazepines—drugs commonly used to treat anxiety, insomnia and seizures—are at increased risk of developing dementia.
Posted in -
Benzodiazepines Don’t Increase Dementia Risks in Older Adults, USC Study Finds
There is little evidence that older adults prescribed benzodiazepines are at increased risk of developing dementia.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models
Researchers use the Future Elderly Model to estimate potential benefits of disease-modifying therapies for Alzheimer disease.
Categorized in -
Race and Ethnic Differences in the Association Between Alzheimer’s Disease Risk and Use of Prescription Medications for Chronic Conditions
Schaeffer Center experts analyze the connection between medications for chronic diseases and their impact on Alzheimer’s as well as a lack of representation among racial and ethnic minorities in clinical trials.
Categorized in -
The Unequal Causes and Costs of Dementia
Dementia and its costs aren’t equally borne by all populations. Studies indicate that, compared to older non-Hispanic white adults, older Black adults are about twice as likely to have dementia, and older Hispanic adults about one and one-half times as likely.
Categorized in -
The Science of Alzheimer’s Disease and Related Dementias (ADRD) for Social Scientists Program
This two-day program aims to provide social science researchers with biomedical and clinical foundations of ADRD.
Categorized in -
Interdisciplinary Hub Fosters Innovative Solutions for Improving Diversity in Clinical Trials
USC has received $5.8 million from Gates Ventures and the American Heart Association to launch a lab aimed at diversifying clinical trials.
Categorized in -
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Schaeffer Center experts propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation.
Categorized in